Shijiazhuang Yiling Pharmaceutical (002603) Q3 2025 earnings summary

Executive summary

• Revenue for the first nine months of 2025 was ¥5.87 billion, down 7.82% year-over-year, while net profit attributable to shareholders rose 80.33% to ¥1.00 billion.

• Q3 net profit attributable to shareholders surged 1,264.61% year-over-year to ¥331.87 million, with basic and diluted EPS at ¥0.1986.

• Operating cash flow for the period increased 296.19% year-over-year to ¥1.28 billion.

Financial highlights

• Gross margin improved as operating costs declined, with total operating costs at ¥4.70 billion for the period.

• Non-recurring gains contributed ¥33.95 million to net profit, mainly from government subsidies and fair value changes.

• Total assets at period-end were ¥14.22 billion, up 6.77% from the previous year-end.

• Shareholders’ equity increased 4.70% to ¥10.70 billion.

Key financial ratios and metrics

• Weighted average ROE for the period was 9.34%, up 4.54 percentage points year-over-year.

• Basic and diluted EPS for the first nine months were ¥0.5988, up 80.31% year-over-year.